|Articles|September 1, 2017
- Pharmaceutical Executive-09-01-2017
- Volume 37
- Issue 9
Pharmaceutical Executive, September 2017 Issue (PDF)
Click the title above to open the Pharmaceutical Executive September 2017 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 8 years ago
Pharm Exec's 16th Annual Industry Auditover 8 years ago
The Supply Chain: What Price Patient Centricity?over 8 years ago
Drug Serialization for DSCSA Compliance Benefits Everyoneover 8 years ago
Pharm Exec's 16th Annual Industry Audit (Overview)over 8 years ago
You Are Pharmaover 8 years ago
Leading With Patients in Mind: Cynthia Schwalmover 8 years ago
FDA, Industry Prepare for New User Fee Initiativesover 8 years ago
Data Inflection Pointover 8 years ago
UK Unveils Post-Brexit Life Sciences Strategyover 8 years ago
Seizing the Opportunity in STEMAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5